Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
SEOUL, South Korea, Feb. 25 /PRNewswire/ -- Dong-A PharmTech Co., Ltd.
announced today that its European licensee, Dr. Falk Pharma, has initiated
a 200 patient, phase 2 proof of concept clinical study to investigate the
use of udenafil, a long acting phosphodiesterase type 5 inhibitor, for
Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,
Its New Long Acting Drug For Erectile Dysfunction
...designed to investigate the efficacy and safety of udenafil
patients with ED. Following a 4-week non-drug b...ndomized to one
of four treatment groups: Placebo, udenafil
udenafil 150mg. The drug treatment period...